文献速递关节外科

丙型肝炎是否影响初次全髋关节置换术中期随访的临床与患者报告结局?

Does Hepatitis C Affect the Clinical and Patient-Reported Outcomes of Primary Total Hip Arthroplasty at Midterm Follow-Up?
PubMed 文献 · J Arthroplasty · 2017-04-11

本研究回顾了2002至2011年间49例丙型肝炎患者的54髋初次全髋关节置换术,并与同期163髋(148例)无丙肝患者匹配对照,平均随访6.5年。丙肝组假体生存率为96.2%,对照组为98.7%;丙肝组翻修风险为对照组的3倍但无统计学显著差异(P=0.26),手术并发症风险更高(比值比=6.5;P=0.034),而术后Harris髋关节评分和加州大学洛杉矶分校活动评分无差异。

要点

  • 丙肝患者初次全髋置换术后假体生存率96.2%,对照组98.7%。
  • 丙肝组翻修风险为对照组3倍,但无统计学显著差异(P=0.26)。
  • 丙肝组手术并发症风险更高(比值比=6.5;P=0.034)。

核心结论

  • 丙型肝炎患者全髋关节置换术后可获得良好的假体生存率和临床结局。
  • 但丙肝患者手术并发症风险和翻修率可能增加。

研究设计与样本

  • 回顾性匹配对照研究,纳入2002至2011年接受初次全髋关节置换术的49例丙肝患者共54髋,并与同期163髋(148例)无丙肝患者匹配对照。
  • 丙肝组包括10例女性和39例男性,平均年龄57岁,平均随访6.5年。
  • 比较假体生存率、并发症率、Harris髋关节评分和加州大学洛杉矶分校活动评分,影像学评估松动、骨折、对线不良和骨溶解。

主要发现

  • 丙肝组假体生存率为96.2%,对照组为98.7%。
  • 丙肝组翻修手术风险为对照组的3倍,但差异无统计学显著(P=0.26)。
  • 丙肝组手术并发症风险更高(比值比=6.5;P=0.034)。
  • 两组术后Harris髋关节评分和加州大学洛杉矶分校活动评分无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is estimated that 3%-6% of orthopedic patients, many of whom may undergo lower extremity total joint arthroplasty, are infected with hepatitis C. The purpose of this study was to assess the outcomes of patients with hepatitis C who undergo total hip arthroplasty (THA) in comparison with a matched control cohort in terms of (1) patient-reported outcomes, (2) implant survivorship, and (3) complications. METHODS: Fifty-four hips in 49 hepatitis C-infected patients who underwent a primary THA between 2002 and 2011 were reviewed. This included 10 women and 39 men who had a mean age of 57 years and a mean 6.5-year follow-up. These patients were matched to 163 THAs (148 patients) who did not have this disease and underwent a THA during the same period. We compared implant survivorship, complication rates, Harris hip scores, and University of California, Los Angeles, activity scores. Radiographs were evaluated for loosening, fracture, malalignment, and osteolysis. RESULTS: The implant survivorship in the hepatitis C-infected patients and comparison group was 96.2% and 98.7%, respectively. The risk of revision surgery in the hepatitis C cohort was 3-fold higher than the comparison group; however, this difference was not significant (P = .26). The hepatitis C-infected cohort had a higher risk of surgical complications (odds ratio = 6.5; P = .034). There were no differences in postoperative Harris hip scores or University of California, Los Angeles, activity scores between the cohorts. CONCLUSION: Hepatitis C patients can achieve good implant survivorship and clinical outcomes after THA. However, these patients may be at an increased risk for surgical complications and revision rate.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Issa K, Pierce TP, Harwin SF, et al. Does Hepatitis C Affect the Clinical and Patient-Reported Outcomes of Primary Total Hip Arthroplasty at Midterm Follow-Up? J Arthroplasty. 2017. PMID: 28478187. doi:10.1016/j.arth.2017.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。